{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:32:46Z","timestamp":1792132366980,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003390","name":"Fritz Thyssen Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003390","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jacl.2018.04.002","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T12:05:06Z","timestamp":1524053106000},"page":"972-980.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A\u00a0model that explores the efficacy of conventional and novel lipid-lowering therapy"],"prefix":"10.1016","volume":"12","author":[{"given":"Merel L.","family":"Hartgers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Besseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke","family":"Wittekoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost H.W.","family":"Rutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L.J.","family":"Visseren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben P.M.","family":"Imholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine E.","family":"Roeters van Lennep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roeland","family":"Huijgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2018.04.002_bib1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.04.002_bib2","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","article-title":"Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen general population study estimated a prevalence of 1 in 217","volume":"37","author":"Benn","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.04.002_bib3","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1093\/eurheartj\/ehs038","article-title":"Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants","volume":"33","author":"Huijgen","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.04.002_bib4","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2018.04.002_bib5","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.04.002_bib6","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.04.002_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2018.04.002_bib8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.atherosclerosis.2014.02.021","article-title":"Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects","volume":"234","author":"Beliard","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2018.04.002_bib9","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(14)62115-2","article-title":"Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"385","author":"Kastelein","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.04.002_bib10","author":"Kenilworh"},{"key":"10.1016\/j.jacl.2018.04.002_bib11","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2018.04.002_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.04.002_bib13","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.04.002_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and Safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2018.04.002_bib15","first-page":"S412","article-title":"Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice","volume":"12","author":"Ohsfeldt","year":"2006","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jacl.2018.04.002_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9343(02)01303-7","article-title":"Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice","volume":"113","author":"Frolkis","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2018.04.002_bib17","doi-asserted-by":"crossref","first-page":"e9220","DOI":"10.1371\/journal.pone.0009220","article-title":"Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal","volume":"5","author":"Huijgen","year":"2010","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jacl.2018.04.002_bib18","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamainternmed.2017.2449","article-title":"Effect of electronic reminders, financial incentives, and social support on outcomes after myocardial infarction: the heartstrong randomized clinical trial","volume":"177","author":"Volpp","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacl.2018.04.002_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(00)03587-X","article-title":"Review of first 5 years of screening for familial hypercholesterolaemia in The Netherlands","volume":"357","author":"Umans-Eckenhausen","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.04.002_bib20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jama.2015.1206","article-title":"Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus","volume":"313","author":"Besseling","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2018.04.002_bib21","first-page":"391","article-title":"Evaluation of the cholestech L.D.X. desktop analyser for cholesterol, HDL-cholesterol, and triacylglycerols in heparinized venous blood","volume":"32","author":"Cobbaert","year":"1994","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"10.1016\/j.jacl.2018.04.002_bib22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2018.04.002_bib23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2013.12.020","article-title":"Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers","volume":"233","author":"Besseling","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2018.04.002_bib24","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00439-001-0628-8","article-title":"The molecular basis of familial hypercholesterolemia in The Netherlands","volume":"109","author":"Fouchier","year":"2001","journal-title":"Hum Genet"},{"key":"10.1016\/j.jacl.2018.04.002_bib25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1034\/j.1399-0004.2000.570205.x","article-title":"Molecular genetic testing for familial hypercholesterolemia: spectrum of LDL receptor gene mutations in The Netherlands","volume":"57","author":"Lombardi","year":"2000","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacl.2018.04.002_bib26","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.04.002_bib27","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.04.002_bib28","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1742-1241.2007.01538.x","article-title":"Effectiveness of statins in Medicare-eligible patients and patients <65 years using clinical practice data","volume":"61","author":"Fox","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacl.2018.04.002_bib29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0735-1097(17)33548-9","article-title":"Persistence and adherence with proprotein convertase subtilisin\/kexin type 9 inhibitors in clinical practice","volume":"69","author":"Hines","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.04.002_bib30","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.amjsurg.2016.07.010","article-title":"Pre-injury polypharmacy predicts mortality in isolated severe traumatic brain injury patients","volume":"213","author":"Catapano","year":"2017","journal-title":"Am J Surg"},{"key":"10.1016\/j.jacl.2018.04.002_bib31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCGENETICS.111.962456","article-title":"Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH","volume":"5","author":"Huijgen","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"issue":"4","key":"10.1016\/j.jacl.2018.04.002_bib32","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jacl.2017.05.016","article-title":"Long-term treatment adherence to the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years","volume":"11","author":"Farnier","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2018.04.002_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2014.09.039","article-title":"Impact of postdischarge statin withdrawal on long-term outcomes in patients with acute myocardial infarction","volume":"115","author":"Kim","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2018.04.002_bib34","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.jacl.2018.04.002_bib35","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice","volume":"38","author":"Landlinger","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.04.002_bib36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/CIRCGENETICS.110.959239","article-title":"Assessment of carotid atherosclerosis in normocholesterolemic individuals with proven mutations in the low-density lipoprotein receptor or apolipoprotein B genes","volume":"4","author":"Huijgen","year":"2011","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacl.2018.04.002_bib37","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add nonstatin therapy: a quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.04.002_bib38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2016.04.054","article-title":"Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality","volume":"68","author":"Besseling","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.04.002_bib39","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.04.002_bib40","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.04.002_bib41","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.04.002_bib42","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk","volume":"318","author":"Ference","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2018.04.002_bib43","author":"Merck Provides Update on Anacetrapib Development Program"},{"key":"10.1016\/j.jacl.2018.04.002_bib44","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/MOL.0000000000000428","article-title":"Novel lipid modifying drugs to lower LDL cholesterol","volume":"28","author":"Cupido","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2018.04.002_bib45","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jacl.2017.02.014","article-title":"Proprotein convertase subtilisin\/kexin 9 inhibition in patients with familial hypercholesterolemia: initial clinical experience","volume":"11","author":"Galema-Boers","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2018.04.002_bib46","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.04.002_bib47","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of Bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418302009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418302009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:33:58Z","timestamp":1761831238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287418302009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1933287418302009"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2018.04.002","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A\u00a0model that explores the efficacy of conventional and novel lipid-lowering therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2018.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}